Julie Saiki - 02 Nov 2026 Form 4 Insider Report for Azora Therapeutics, Inc. (DE) (AZR)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
04 Nov 2026, 16:53:56 UTC
Prior SEC filing
30 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Matthew Davidson, Attorney-in-Fact
Filing notes and source

Key filing fact

Julie Saiki filed Form 4 for Azora Therapeutics, Inc. (DE) (AZR) on 04 Nov 2026.

Key facts

  • This page summarizes Julie Saiki's Form 4 filing for Azora Therapeutics, Inc. (DE) (AZR).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 04 Nov 2026, 16:53.

Change

  • Previous filing in this sequence was filed on 30 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002154197 Primary reporting owner

Saiki Julie

Relationship
Chief Strategy Officer
Address
C/O AZORA THERAPEUTICS, INC., 16501 VENTURA BLVD., SUITE 400, ENCINO
Signature
/s/ Matthew Davidson, Attorney-in-Fact
Signature date
04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AZR transaction

Common Stock

Conversion of derivative security

Transaction value
Shares
+626,252
Change %
+463%
Price
Shares after
761,636
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AZR transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares
-626
Change %
-34%
Price
$0.000000*
Shares after
1,226
Date
02 Nov 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
626,252
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Subject to certain beneficial ownership and other limits set forth in the Certificate of Designation of the Series A Preferred Stock, each share of Series A Preferred Stock converted into 1,000 shares of the Issuer's common stock and has no expiration date.

Footnote F2

The Series A Preferred Stock converted automatically within three days of Issuer's stockholders approving a proposal for the issuance of Issuer common stock upon conversion of the Series A Preferred Stock pursuant to the terms of the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer, Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer, and a private Delaware corporation that was then known as Azora Therapeutics, Inc.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .